In silico assessment of antiarrhythmic effects of drug ranolazine on electrical activity in human ventricular myocardium by Abbasi, Mitra & Polak, Sebastian
In silico Assessment of Antiarrhythmic Effects of Drug Ranolazine on Electrical 
Activity in Human Ventricular Myocardium  
Mitra Abbasi1, Sebastian Polak1,2 
1Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield, UK 
 2Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland  
Abstract 
The aim of this study was to simulate the 
electrophysiological modifications by the ranolazine at 
the left ventricular wall level by using in vitro 
electrophysiological measurements from canine 
ventricular myocytes to generate early information on 
cardiac safety in the human heart. The antiarrhythmic 
effect of ranolazine on two proarrhythmic drugs was 
examined.  
The sensitivity of ionic currents to ranolazine was 
described as Action Potential Duration (APD) variations 
in response to different therapeutic concentrations. The 
observed results can be explained by the interplay 
between inhibition of the INaL and IKr currents. 
Simulation results are in agreement with in vitro and in 
vivo studies of arrhythmia and confirmed the 
antiarrhythmic properties of ranolazine which may be 
utilized for suppressing ventricular arrhythmias. 
1. Introduction
Ranolazine is an antianginal compound, approved by 
the US Food and Drug Adminstration (FDA) [1,2] 
without significant hemodynamic fluctuations (e.g 
bradycardia or hypotension). However, ranolazine has 
been known to produce a small prolongation of the QT 
interval [1]. Some experimental evidences [2–5] indicated 
the ant-ischaemic effects of ranolazine which relate to 
inhibition of the late inward sodium current (INaL) during 
cardiac repolarisation. Although several experimental 
studies [5–7] have shown a potent of antarrhythmic effect 
of ranolazine against cardiac (atrial and ventricular) 
arrhythmias, the potential antiarrhythmic effects of 
ranolazine need to be investigated in humans. 
This study designed to evaluate the potential 
antiarrhythmic actions of ranolazine. For this purpose, a 
combination of ranolazine with class III antiarrhythmic 
drugs (dofetilide and d,l-sotalol) is used to examine the 
effects of inhibition of INaL on top of IKr block. The 
current study demonstrates the impact of these drugs on 
APD prolongation and the underlying 
electrophysiological effect of ranolazine in a human 
ventricular myocytes cell model [8]. 
2. Methods
This study was designed to provide safety 
pharmacology modelling and simulation approaches to 
develop an in-silico tool for preclinical antiarrhythmic 
drug safety assessment by demonstrating the impact of 
dose/concentation relationship of drugs on ventricular 
arrhythmias biomarkers (i.e. APD, ∆APD). We obtained 
∆APD values ((∆APD = APD with ionic current 
inhibition (Table 1,2 and 3) – APD placebo (under 
control conditions)) from simulation models using 
experimental values from [9,10].  
We used the Cardiac Safety Simulator (CSS V2.0, 
Simcyp, Sheffield) to evaluate the cardiac 
electrophysiological effects of ranolazine and its 
interaction with two class III antiarrhythmic drugs. 
2.1. Model input data 
We used previously published data [9], as presented in 
Table 1, where half maximal inhibitory concentrations 
(𝐼𝐼𝐶𝐶50) of ranolazine for five different ionic channels (i.e. 
the rapid delayed rectifier potassium current (𝐼𝐼𝐾𝐾𝐾𝐾  /hERG), 
sodium current (𝐼𝐼𝑁𝑁𝑁𝑁/Nav1.5), late inward sodium current 
(INaL), L-type calcium current (𝐼𝐼𝐶𝐶𝑁𝑁/Cav1.2), slow delayed 
rectifier current (𝐼𝐼𝐾𝐾𝐾𝐾/KCNQ1 + KCNE1) with h to 
describe the drug triggered ionic current modifications 
and the drug concentration (µM). 
We used drug concentrations and inhibitory actions of 
dofetilide and d,l-sotalol on ion channels in vitro from 
previously published data [10] as presented in Tables 2 
and 3. Inhibitory actions (i.e. the dose-inhibition 
relationship) of these two compounds were specified at 
ion channels by using multiples of the free effective 
therapeutic plasma concentration (𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢) of the 
drug at 1, 10, 30, 50, 75 and 100 fold of their respective 
 
Computing in Cardiology 2016; VOL 43 ISSN: 2325-887X  DOI:10.22489/CinC.2016.309-284 
  
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢  value (Tables 2 and 3). We scaled from the 
original values obtained on CHO cells at room 
temperature to HEK cells at physiological temperature as 
the standard in vitro system for each set of data. 
Simulations were performed by using data presented in 
Table 4, in order to test the potent late sodium (INaL) 
blocking actions of ranolazine on suppressing 
arrhythmias induced by dofetilide and d,l-sotalol at 
different concentration. 
Table 1. Drug concentrations and inhibitory actions of 
ranolazine on ion channels in vitro 
Effects of ranolazine on cardiac transmembrane ion 
currents [9] 
Ion Channel current Inhibitory Potency 𝐼𝐼𝐶𝐶50 (µM) 
Inward 
𝐼𝐼𝑁𝑁𝑁𝑁 294 
𝐼𝐼𝑁𝑁𝑁𝑁𝑁𝑁  5.9 
𝐼𝐼𝐶𝐶𝑁𝑁𝑁𝑁  296 
Outward 
𝐼𝐼𝐾𝐾𝐾𝐾  11.5 
𝐼𝐼𝐾𝐾𝐾𝐾 30 
𝐼𝐼𝐾𝐾1 no effect 
𝐼𝐼𝑡𝑡𝑢𝑢 no effect 
Drug 
concentrat
ion (µM) 
Placebo 2 4 5 10 15∗ 
* We assessed the drug actions at concentrations
exceeding the plasma levels found in clinical trials (>10 
µM) [11]. 
Table 2. Drug concentrations and inhibitory actions of 
dofetilide on ion channels in vitro  
Inhibitory actions of dofetilide on ion channels [10] 
Fracti
on 
conc. 
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢
(µm) 
𝐼𝐼𝑁𝑁𝑁𝑁 𝐼𝐼𝐶𝐶𝑁𝑁 𝐼𝐼𝐾𝐾𝐾𝐾
𝐼𝐼𝐶𝐶50 h 𝐼𝐼𝐶𝐶50 h 𝐼𝐼𝐶𝐶50 h 
×1 0.0016 
124.
45 
0.3
2 
184
.1 
0.8
9 
0.0
38 
1.9
8 
×10 0.016 
×30 0.048 
×50 0.08 
×75 0.12 
Table 3. Drug concentrations and inhibitory actions of 
d,1-sotalol on ion channels in vitro.  
Inhibitory actions of d,l-sotalol on ion channels [10] 
Fraction conc. 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢 
𝐼𝐼𝐾𝐾𝐾𝐾  
𝐼𝐼𝐶𝐶50 h 
×1 14.68 
356.4 1.023 
×10 146.8 
×50 734 
×75 1101 
×100 1468 
Table 4. Drug concentrations data to assess drug-drug 
interactions of ranolazine with two unsafe compounds 
Ranolazine effects on dofetilide and d,1-sotalol 
Substrate Drug concentration (µM) 
ranolazine 15 
dofetilide 0.0016 0.016 0.048 0.08 0.12 
d,l-sotalol 14.68 146.8 734 1101 1468 
2.2. Human ventricular cell model 
The computational models for endocardial (endo) cell 
type were derived from the O'Hara-Rudy dynamic (ORd) 
human ventricular model [8] by proportionally changing 
ionic currents based on in vitro measurements. 
2.3. Cardiac Safety Simulator (CSS) 
 To assess the antiarrhythmic potency of the ranolazine 
and its interactions with the other two compounds, the 
CSS platform (V2.0) was used to simulate normal 
(control) physiological and drug-induced patho-
physiological alterations in cardiac AP conduction at the 
population level (i.e. Sim-NEurCaucasian, North 
European Caucasian) [12]. The variability in the 
Sarcoplasmic reticulum volume was set to 30% CV 
providing an estimate of the scale of variation. 
3. Results
3.1. Electrophysiological effects 
The effect of ranolazine on the AP of human 
ventricular endo cells is shown in Figure 1. Results show 
ranolazine has no effect on resting membrane potential 
and this is because of the lack of effect of the compound 
on the inward rectifier potassium channel current (𝐼𝐼𝐾𝐾1). 
This drug has no influence on AP amplitude in ventricular 
myocytes. Ranolazine caused a small concentration-
dependent lengthening of APD in endo cell. 
Figures 2, 3 and 4 illustrate changes in APD (∆APD) 
for ranolazine, d,l-sotalol and dofetilide respectively. The 
∆APD increasingly grows by increasing dose for each 
compound. The concentration-dependent prolongation of 
APD that was greater at 90% than at 50% repolarization. 
Although ∆APD is very small for ranolazine, the larger 
extent of APD prolongations are shown for d,l-sotalol and 
dofetilide that are associated with the Class III action of 
blocking 𝐼𝐼𝐾𝐾𝐾𝐾  which can lead to torsade de points. 
 
 
  
Figure 1. Concentration-dependent effects of ranolazine 
on cellular APs in the ORd endocardial human cell 
model. 
Figure 2. Concentration-dependent effects of ranolazine 
on ∆APD mutation in human ventricular myocyte. 
Adminstration of clinical range (ie, 2 to 6 µM) and high 
therapeutic ranolazine (>10 µM) prolongs APD 
moderately. 
Figure 3. Concentration-dependent effects of d,l-sotalol, a 
selective 𝐼𝐼𝐾𝐾𝐾𝐾  blocker, on ∆APD mutation in human 
ventricular myocyte. Adminstration of d,l-sotalol 
produces a proportional increase in APD.  
Figure 4. Concentration-dependent effects of dofetilide on 
∆APD mutation in human ventricular myocyte. Dofetilide 
shows significant increase in APD for the concentration 
range (0.048 to 0.12 µM) .  
3.2.  Drug-drug interactions 
The simulations were performed for a fixed 
concentration of the ranolazine (15 μM) with a 
combination of dofetilide and d,l-sotalol to evaluate 
experimental and/or clinical measures of 
electrophysiological effect on ventricular myocytes. The 
effect of ranolazine is shown at different concentrations 
of two selective 𝐼𝐼𝐾𝐾𝐾𝐾  blocker compounds (Figures 5 and 6). 
Despite primary prolongation of APD of the in-vitro-
modelled electrophysiology on both drugs, ranolazine 
shortened the APD, leading to suppression of the 
dofetilide and d,l-sotalol for the initiation/maintenance of 
ventricular arrhythmias. 
Figure 5. Impact of ranolazine (at 15 µM) , with the 
combination of different d,l-sotalol plasma 
concentrations, on ∆APD mutation (∆𝐴𝐴𝐸𝐸𝐴𝐴50 and 
∆𝐴𝐴𝐸𝐸𝐴𝐴90) in human ventricular myocyte. Ranolazine (15 
µM) abbreviates the prolonged ventricular endocardial 
APD which is produced by d,1-sotalol at a concentration 
of (≥734 µM). 
Figure 6. Impact of ranolazine (at 15 µM), with 
combination of different dofetilide plasma concentrations, 
on ∆APD mutation (∆𝐴𝐴𝐸𝐸𝐴𝐴50 and ∆𝐴𝐴𝐸𝐸𝐴𝐴90) in human 
ventricular myocyte. Ranolazine (15 µM) abbreviates the 
prolonged ventricular endocardial APD which is 
produced by dofetilide at a concentration of (≥0.048 µM). 
 
 
  
4. Discussion and conclusions
This study determined the impact of the antiarrhythmic 
effect of ranolazine on the cardiac cell electrophysiology 
mechanism and its interaction with proarrhythmic drugs. 
The aim was to investigate the electrophysiological 
effects of ranolazine at concentrations within the 
therapeutic range (i.e., 2 to 6 µM) and supertherapeutic (≥ 
10 µM ) including inhibition of INaL , ICaL and IKr .  
As shown in Figures 1 and 2, ranolazine prolongs APD 
modestly due to the Inhibition of IKr . Although ranolazine 
slightly prolonged APD, it reduced the increase in APD 
induced by the selective IKr blockers d-sotalol and 
dofetalide in human cardiac ventricles (Figure 7), which 
demonstrates the pharmacological effect of ranolazine 
including inhibition of INaL, ICaL and IKr currents [4]. 
Figure 7. Summary of the electrophysiological effects of 
compounds on ventricular myocytes and their interactions 
with ranolazine. Note: Conc. represents drug plasma 
concentrations used individually or in combination with 
drugs (Concentration values are shown in Figures 2-6). 
Our results support the major role of the inhibition of 
INaL and IKr in modulation and the reduction of APD by 
ranolazine, despite a modest increase in the APD, based 
on data from animal ventricular myocytes. The dynamic 
behaviour and the response to simulated ventricular 
myocytes in these models were consistent with 
experimental observation [4,9,11]. 
In our future work, we will investigate the underlying 
anti-arrhythmic action of ranolazine mechanisms 
including metabolic and antiischaemic influences in 
human ventricular moyocytes.  
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